Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine

Experts in oncology discuss future directions in biomarker-driven therapy.

Dr Mark Socinski describes the design and findings of the CRESTONE trial.

Dr Jyoti Patel presents data from the ARROW clinical trial.

Lori Wirth, MD, reviews the phase 1/2 LIBRETTO-001 trial.

Expert oncologists discuss RET-driven therapy for select solid tumors.

Experts discuss their personal experiences when treating patients with NRTK fusions and solid tumors.

Jonathan Trent, MD, PhD, describes the safety and efficacy data from clinical trials of larotrectinib in patients with NRTK fusion–positive solid tumors.

Benjamin Levy, MD, reviews the available treatment options for patients whose tumors harbor NRTK fusions.

Dr Lori Wirth describes the importance and implications of testing for NRTK fusions in patients with solid tumors.

Dr Mark Socinski and panel discuss the challenges and unmet meets of biomarker-driven therapy across solid tumor types.

Experts in oncology provide their insights on the use of companion diagnostics in the treatment of solid tumors. 

A panel of oncology experts in lung, thyroid, and sarcomatous tumors discuss the role and impact of pan-tumor biomarker testing.

Jyoti Patel, MD, FASCO, discusses the pros and cons of tissue versus blood for molecular testing of solid tumors.

Benjamin Levy, MD, and a multispecialty panel of experts discuss the importance of biomarker-directed therapy for appropriate solid tumors.